{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-26-001347","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-03-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.018426+00:00","generated_at":"2026-05-15T17:59:55.662549+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"InMed provides 2026 pipeline outlook; pre-IND meetings targeted for INM-901 and INM-089","bullets":["Preclinical data for INM-901 shows reduced neuroinflammatory biomarkers, neuroprotection, and behavioral improvements in Alzheimer's models.","Targeting pre-IND meeting with FDA for INM-901 in Q3 2026 and for INM-089 in Q4 2026.","INM-901 aims for IND submission and Phase 1 clinical trial initiation in 2027.","INM-089 (dry AMD) completed dose-ranging studies; drug substance process in place for IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-26-001347","json":"https://secwatch.observer/filing/0001062993-26-001347.json","markdown":"https://secwatch.observer/filing/0001062993-26-001347.md","text":"https://secwatch.observer/filing/0001062993-26-001347.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326001347/0001062993-26-001347-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000106299326001347/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T17:59:55.662549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}